Tuberculosis (TB) remains one of the most persistent infectious diseases globally.
Despite decades of research and medical advancements, TB continues to impact millions of lives each year. According to the World Health Organisation (WHO), an estimated 10.6 million people fell ill with TB in 2022, making it one of the leading causes of death from infectious diseases worldwide.
World TB Day is not only a moment of awareness.
It is a reminder that scientific progress must continue consistently and reliably.
The Challenge
Tuberculosis is complex.
It involves:
- Latent and active infection states
- Variable immune responses
- Long treatment cycles
- Challenges in early detection
Because of this, TB research requires precision at every stage.
From identifying biomarkers to validating diagnostic tools, the margin for error is small.
Even minor inconsistencies in data can affect outcomes.
Role of Immunoassays in TB R&D
Immunoassays such as ELISA continue to play a critical role in:
- Cytokine profiling
- Antigen detection
- Biomarker validation
- Monitoring immune responses
These tools help researchers understand how the body responds to TB infection and how diagnostic markers behave across populations.
Importantly, ELISA-based systems offer:
- High sensitivity
- Quantitative output
- Scalability across studies
This makes them essential for both research and early-stage diagnostic development.
The Importance of Reproducibility
Scientific discovery is only valuable if it can be repeated.
In TB research, reproducibility ensures that:
- Results are consistent across laboratories
- Diagnostic tools perform reliably
- Clinical translation is possible
Without reproducibility, promising findings cannot move forward.
At scale, this can delay innovation.
Where do we fit in?
At deNOVO Biolabs, we do not develop TB therapies.
We support the science behind them.
Our focus is on enabling researchers and biotech teams through:
- ELISA kits for biomarker detection
- Antibodies and recombinant proteins
- Custom assay development
- Validation support for research workflows
These tools are used by:
- Biopharma companies
- CROs
- Academic research institutions
working across infectious diseases, including tuberculosis.
Looking Ahead
Ending TB is not a single breakthrough.
It is a continuous process built on:
- Scientific rigour
- Strong diagnostics
- Reliable data
- Collaborative ecosystems
World TB Day reminds us that progress in global health depends not only on innovation, but on how well that innovation is measured and validated.
If your team is working on:
• Infectious disease research
• Biomarker discovery
• Diagnostic development
and requires reliable, validated assay solutions, we would be happy to collaborate.
📩 info@denovobiolabs.com
🌐 www.denovobiolabs.com